This report explores two scenarios for diabetes care by 2030, focusing on the impact of obesity and chronic diseases, and the potential for innovative business models in pharmaceuticals and healthcare.
(Generated with the help of GPT-4)
| Quick Facts | |
|---|---|
| Report location: | source |
| Language: | English |
| Publisher: |
Novo Nordisk |
| Authors: | Lene Bjørn Serpa, Bo Wesley |
| Time horizon: | 2030 |
| Geographic focus: | Global |
The research method involved scenario building, drawing on trends in political, socio-economic, cultural, technological, governance, and demographic areas. It identified key drivers affecting Novo Nordisk's strategy and business design, focusing on geopolitical landscapes, economic power shifts, resource constraints, and social changes. The scenarios were developed using insights from various stakeholders and experts.
(Generated with the help of GPT-4)
The report presents two scenarios, “The new normal” and “No outcome, no pay,” outlining future developments in public health and diabetes care. It examines the continued growth of the obesity pandemic, the effectiveness of public health interventions, and the role of surgery and pharmaceuticals. It also considers the potential shift towards rewarding health outcomes over products, the impact of full cycle care delivery, and the challenges of providing diabetes care globally.
(Generated with the help of GPT-4)
Categories: 2030 time horizon | 2030s time horizon | English publication language | Global geographic scope | care | chronic diseases | diabetes care | food | full cycle care | government intervention | health diabetes | health outcomes | interventions | medical intervention | medical market | obesity | partnerships | pharmaceutical business models | public health | surgery